

Patient Safety and the Implementation of the Falsified Medicines Directive in the Hospital Environment

Practical solutions and benefits



Contents

GLOSSARY OF TERMS	2
BENEFITS FOUND IN HOSPITALS FOLLOWING IMPLEMENTATION OF THE FMD USING AUTOMATION	3
FOREWORD	4
MEP Manuel Pizarro, Member of the European Parliament, Socialists & Democrats Group, Portugal	4
Mike Isles, Executive Director, European Alliance for Access to Safe Medicines	5
EXPERT VIEWS ON THE FALSIFIED MEDICINES DIRECTIVE	6
THE IMPACT OF COVID-19 ON SUPPLY CHAINS	8
What are the most popular fake pharmaceuticals sold?	8
Raising public awareness is essential	9
What kind of medicines do you want to buy/have you bought?	10
The NABP Top Level Domain name program .Pharmacy	10
THE PRACTICAL STEPS THAT CAN BE TAKEN TO HELP PROTECT THE HOSPITAL PATIENT	11
STATUS OF THE EUROPEAN AND FINNISH MEDICINES VERIFICATION SYSTEMS -	
VARIABLE PROGRESS MADE	12
Alert rate	12
End-users not connected	12
Stabilisation Periods	13
Alert Summary	13
THE CHALLENGES AND BENEFITS OF IMPLEMENTING THE FMD	14
Standardisation is proving key to intraoperability across systems	14
Benefit mapping to maximise FMD implementation potential	14
Cost savings	15
PRACTICAL HURDLES AND CHALLENGES OF IMPLEMENTING THE FMD	40
IN A FRENCH AND UK HOSPITAL	16
Julia Asplin, Pharmacy Logistics Lead and Purchasing Team manager Lister Hospital Stevenage, UK	16
Valerie Pelletier, hospital pharmacist, Supply Chain Manager, Rouen University Hospital	21
EAASM CALL TO ACTION	23

FiMV0

Glossary of Terms

Finnish National Medicines Verification Organisation ASOP EU Alliance for Safe Online Pharmacy in the EU Falsified Medicines Directive FMD EAHP European Hospital Pharmacy Association NABP National Association of Boards of Pharmacy **EAASM** European Alliance for Access to Safe Medicines **NMVO** National Medicines Verification System **EFPIA** European Federation of Pharmaceutical Industry **OECD** Organisation for Economic Co-operation and Associations Development European Medicines Verification Organisation TLD Top Level Domain Name **EMVO EUIPO** European Intellectual Property Office URL Uniform Resource Locator FDA Federal Drug Administration SOP Standard Operating Procedure

Benefits found in hospitals following implementation of the FMD using automation

- Automated solutions result in a reduced manual scanning burden of up to 63%
- No extra staff required to run a robotic system and frees time for resources to be directed towards improving pharmaceutical services

Robotics allows:

- Guaranteed inventory management
- Reduced inventory resulting in cost savings
- Improved ordering for bulk lines
- A vital part of the medication process secured
- Automatic decommissioning for a significant part of the internal supply chain
- Visibility of recycled/returned products allows for analysis and subsequent improvements
- Utilisation of technology has across-the-board ramifications and opportunities for IT
- Redesigned workflows optimise "goods in" and "goods out"
- Very positive development of relationships with commercial provider to support development of NHS
- Adaptations ongoing to accommodate both FMD and local operational

Foreword



MEP Manuel Pizarro European Parliament S&D group



It is an alarming fact that the COVID pandemic has highlighted the issue of falsified medicines as a plethora of COVID-19 web scams have been observed preying on the fear and anxiety of the public. Of course we should remind ourselves that, whilst the FMD protects the legitimate supply chain, we need to be aware that patients and consumers can be duped into buying medicines from websites selling medicines illegally. So I encourage you all to play your part, as indeed I will do, to raise public awareness around this disturbing criminal-led abuse. We must also encourage public-facing campaigns as research indicates there is a woeful lack of awareness amongst the public of these websites which are operating illegally.

With the launch of vaccines, this will inevitably give rise to fraudulent cyberspace activity. One simple and strong message for all peoples around the world is that there will never, ever be a vaccine sold via a website. If one is found using this method of sale, it can only be a falsified vaccine.

The fact that the Commission is now looking closely to develop a new fit-for-purpose Digital Services Act to replace the 20-year-old e-Commerce Act is to be welcomed. Activities by the EUIPO/Observatory where they have created a number of expert groups which includes "Collaboration with Intermediaries" will bolster the evidence on which the Commission can act.

Turning back to the legitimate supply chain, it is a well-known fact that the Falsified Medicine Directive has put the EU at the vanguard of securing a supply chain for patient safety. The inclusion of a unique identifier on each prescription pack has been a hugely complicated task. And whilst the introduction of the FMD has proved difficult within the hospital environment, we heard today that once implemented, benefits beyond simply authenticating the medicine are achieved, with an acceleration of modernity within the existing pharmacy department footprint. Greater connectivity to other aspects of hospital systems was found; this impacts positively on patient safety, whilst also resulting in more accurate product recall and more efficient inventory levels with ensuing cost reductions.

I therefore commend the good work of all those parties involved in implementing the FMD in hospitals, which will add another layer of patient safety.



Mike Isles
Executive Director,
European Alliance for
Access to Safe Medicines



This meeting on the implementation of the Falsified Medicines Directive (FMD), is the second that the EAASM has organised. Both had the aim to provide practical solutions to help hospitals deliver this important step. As before, we heard from the organisations that form the backbones of the IT infrastructure, without which the authenticity of packs could not be verified. The overview by the European Medicines Verification System, shows good progress in terms of a downward trend of false product alerts. However, it was also somewhat surprising to note that 22 countries were now beyond the allowed stabilisation period and so moving into uncharted waters with the EU Commission in terms of future actions required to deliver a fully functional FMD.

It was most encouraging to note that the appraisal of the Finnish system was very positive with an alert rate of 0.8% which was often the result of scanning issues and not detection of a falsified medicine. The overview by the European Association of Hospital Pharmacists (EAHP) clearly showed that challenges still existed and ranged from non-compatible infrastructure to limitations from software providers to integrate the systems. On the positive side, also echoed by a report commissioned by the European Federation of Pharmaceutical Industry Associations (EFPIA), additional improvements were anticipated in stock management and traceability of medicines. In fact, one analysis showed that at one hospital, it resulted in cost savings to the value of 4.4 million euros per annum due to better management of inventory and ordering patterns. Most importantly the report stated that an FMD implementation exercise provided a platform for better inventory and procurement, an ability to recall accurately and efficiently, and benefits with dealing with local shortages and repacking identification.

Focusing on the actual practical steps for a successful implementation, two experienced hospital pharmacists took the opportunity to describe this process. Whilst it was a complex and time-consuming exercise, it was regarded as an essential step forward. This had equipped the hospital to meet the new digital environment. It had also opened up diagnostic gains via artificial intelligence, enhanced inventory planning and medication traceability pathways, all of which contributed greatly to patient safety.

The EAASM sincerely hopes that this report will be read by the hospital pharmacy community and that it elicits discussion so that the lessons learned can be put to good purpose by any hospital embarking on implementing the FMD.

Expert views on the Falsified Medicines Directive

Maija Gohlke-Kokkonen, General Manager, Finnish National Medication Verification Organisation

percentage of "alerts" starting from February 2019 has been low at 0.08% and is decreasing. However, these alerts are not due to falsified medicines but to scanning, data

"It is good to report that the management and non-EU serialised improvement. A joint effort will be packs' issues. Transactions having stabilised at just below 15,000 per providing a secure supply chain for month are now also on the increase. the COVID-19 vaccines in the Hospitals have reported aggregation verification system." and 2D printing quality as areas for

required as we all engage in





Grant Courtney, Consultant for the Be4ward expert supply transformers consultancy

"The report commissioned by the anchor within the hospital and so been achieved due to better Federation of Pharmaceutical Industries (EFPIA) clearly Associations illustrates the benefits of implementing the FMD in hospitals. This is because serialised prescription packs act as a data of 4.4 million euros per annum had healthcare provider."

enables greater visibility, both from management of inventory and and a logistics perspective but more ordering patterns. These barcodes importantly, allows for greater are also opening up the opportunity traceability and thus enhances to digitally web-enabled products, patient safety. In one hospital, allowing the provision of live data significant cost savings to the value and services directly to the

Be4ward



Julia Asplin, Pharmacy Logistics Lead and Purchasing Team Manager, The Lister Hospital, Stevenage, UK

chosen to spearhead the implementation. This gave us the opportunity to reconfigure and thus optimise workflows which resulted in greater teamwork, cohesion and efficiency gains in many areas.

"A proven robotics system was There were 10 phases which took savings. In addition, to be able to

one year to complete but it was so secure further the medication worth it, as using an automated process from a patient safety point solution reduced the manual of view, is so important. Combine scanning burden by up to 63%. The this with an opportunity to re-vitalise results were, guaranteed inventory a continuous improvement culture management with subsequent cost and you have a recipe for success."

NHS



Valerie Pelletier, Hospital Pharmacist, Supply Chain Manager, Rouen University Hospital, France

decommissioning

"The use of an automated we still face challenges such as can take place. Despite this, it is vital dispensing system means that dispensing issues due to a lack of automatically, and with no extra staff packs and medicines wrapped in associated benefits." needed. This has greatly enhanced plastic film combined with a need to our operational efficiency. However, unpack each carton so that scanning

that all hospitals in France undergo is done serialisation on a percentage of automation which has so many





Agnès Mathieu-Mendes, Deputy Head of Unit B4 Medical products: quality, safety, innovation, DG Health and Food Safety, European Commission

drop in the alert rate and all the hard the various FMD phases has made security of the supply chain and thus work by all those parties involved is the supply chains safer and of a not to be under-estimated. We are better quality. In addition, the online

not over the finish line yet but Common Logo and the safety the FMD."

"Of particular note is the significant" undoubtedly the progress to date via features have greatly enhanced the greatly enhanced patient safety which was the primary objective of



Fanny Trenteseaux, Project & Partner Manager, Legal Partner **Engagement of the European Medicines Verification Organisation (EMVO)**

the number of "Alerts" (this is where

"I am able to summarise the key unique serialised data matrix on the positive news was that the overall take home messages are as follows: prescription pack) still varied greatly trend was downwards as more and between countries, with four on decommissioning of a pack, the countries having alert rates of system does not authenticate the greater than 1%. However, the

more technical issues resolved."





The impact of COVID-19 on supply chains

It is vital that healthcare professionals understand the full background to the rising problem of falsified medicines. The FMD was put in place to safeguard what is often termed the "legitimate" supply chain where the medicine is manufactured by the pharmaceutical company, which is then delivered to a pre-wholesaler and the on to a wholesaler or distributor and then on to the pharmacist (or indeed posted to the patient if the necessary legal documents – e.g. proof of prescription are supplied). If the medicine is parallel imported to another Member State, the pack has to be decommissioned and a new serialised barcode added to the pack.

In March 2020 Europol supported a pan-European operation targeting the illicit online and offline trafficking of misused and falsified medicines.



This operation resulted in 12 organised criminal groups being disrupted with 165 suspects arrested in Belgium, Cyprus, Finland, France, Greece, Hungary, Italy, Portugal, Slovakia, Spain, Ukraine, and the United Kingdom. Incredibly, nearly €1.5 million of assets were recovered with nearly 36 million units of medicines seized (such as pseudoephedrine, anticancer drugs, antihistamines, anxiolytics, erectile dysfunction medicines, hormone and metabolic

regulators, narcotics, painkillers, antioestrogens, antivirals, hypnotics and doping substances) to the value €7.9 million. In addition, a worrying trend was observed where oncological medicines were being stolen from hospitals.¹

The impact of the pandemic cannot be underestimated in terms of the increased use of the Internet to conduct the purchase of items online. Buying medicines online has not escaped a scourge of fraudulent activity preying on the lack of knowledge, fear and anxiety of a vulnerable population.

Certainly, Customs' organisations have seen very big increases year on year as people, in general, seek to buy more and more products online. COVID-19 has accelerated this phenomenon. This makes for a very difficult situation: how can borders adequately control the movements of millions of small packages? One estimate has suggested that over 130 million people are buying medicines online within Europe.

This number was extrapolated from a survey carried out in 2014.² Today one would expect this figure to be much higher, catalysed by the pandemic.



registered and used to spam out advertisements for COVID-themed scams. New domain names fitting these criteria are being registered at the rate of around 1,000 per day.³

Criminal activities require websites and Internet domain names to run phishing, spam and malware campaigns. During March 2020.

at least 100,000 new domain names were registered containing

terms like "covid," "corona," and "virus". Other domains have been

What are the most popular fake pharmaceuticals sold?


A recent report by the OECD⁴, to which ASOP EU & EAASM were asked to contribute, clearly demonstrates that countries such as China and India are playing a key role in this illegal activity.

Examples of falsified/counterfeit pharmaceutical products recorded in the database of customs seizures developed for the OECD/EUIPO (2019) study are various and striking. Over the 2014-2016 period, customs authorities worldwide recorded seizures of medicines for the treatment of malaria, HIV/AIDS and cancer. These pose a very serious threat to consumer health.

However, a quick review of the data suggests that substandard and falsified antibiotics, lifestyle drugs and painkillers were the most targeted by counterfeiters.

A recent study by the National Association of Boards of Pharmacy (NABP)⁵ entitled Rogue RX Activity Report, highlighted the following:

- ★ Dozens of illegal online pharmacies peddling Rx-only medicines marked as COVID-19 treatments
- ★ 100s of newly created domain names, not yet active but may be used in the future



- ★ Government agencies, regulators, members of Congress and state attorneys are cracking down on this activity whilst reaching out to the private sector for support
- ★ Many Internet intermediaries are actively shutting down fraudulent face mask, vaccine and test kit sellers
- ★ However, illegal Internet pharmacies continue, largely unabated

The Rogue Rx Activity report highlighted the following selection of prescription-only medicines that have gained much media attention:

- ★ Chloroquine, azithromycin, and lopinavir/ritonavir. Chloroquine (Aralen®) and hydroxychloroquine (Plaquenil®) are antimalarial drugs that have received emergency use authorisation from Food and Drug Administration (FDA) for the treatment of certain hospitalised COVID-19 patients
- * Azithromycin is being used in combination with chloroquine and hydroxychloroquine
- ★ Lopinavir and ritonavir (sold together under the brand name Kaletra®) are antiretrovirals that are being tested as a possible COVID-19 treatment
- ★ NABP has also identified websites peddling diltiazem, furosemide, and mefloquine all of which are being studied as possible coronavirus treatments

Of course, all these treatments are unproven, and dangerous if taken without proper oversight.

Raising public awareness is essential

A long term public awareness campaign, carried out by ASOP EU and the EAASM over a number of years⁶, revealed vital information about the number and behaviour of would-be purchasers of medicines online. The campaign ran in 5 European countries (France, Germany, Italy, Spain and UK) and was generated by Google Adwords using keywords such as "pharmacy online", "buy medicines", etc. During the campaign no less than 35,000 first page results were recorded per day (this is when the advertisement to the educational website appears on the first page of the Google search results) with 1,200 people per day clicking on the link to the campaign. On each educational page, the viewer had an option to complete a 10 question survey. Over 2,300 surveys were completed.





Rogue Online Pharmacies in the Time of Pandemic: Capitalizing on Misinformation and Fear

What kind of medicines do you want to buy/have you bought?

One key question was which medicines are they looking to buy and the answers revealed that all types of medicines were searched for.

Condition/Medicine for	Respondents
Female contraception, Hair loss, Arthritis, Blood pressure Cancer, Diabetes, Hepatitis, HIV, Cholesterol Lowering, Psychiatric	>6%
Antibiotic therapy	7%
Pain relief	18%
Erectile dysfunction	12%
Other	29%

Another key question revealed a woeful lack of understanding about the risks of buying online but once told of the fact that 96% of websites selling medicines were operating illegally, 91% of people were actually willing to change their behaviour.



The NABP Top Level Domain name program .Pharmacy



Educating consumers about the dangers of such potentially harmful purchases is part of the reason NABP started the .Pharmacy Top Level Domain (TLD) Program.⁷ Pharmacy websites enable consumers to identify safe online pharmacies simply by

looking for ".pharmacy" in a website address/URL.

In addition, one of the .Pharmacy TLD programme standards requires pharmacies using the domain to obtain a valid prescription from the patient. Being able to separate legitimate online pharmacies from rogue internet drug outlets is an essential part of protecting public health. Consumers no longer need to look for safety seals, which can be faked, since the fraud-proof mark of safety is in a .pharmacy website's URL. To see the list of trustworthy .pharmacy websites, visit the Buying Safely section of www.buysaferx.pharmacy.



The practical steps that can be taken to help protect the hospital patient

- ★ All healthcare professionals (especially doctors, pharmacists, nurses and auxiliary staff) should be trained on falsified medicines and the purpose of the FMD
- ★ On entering a hospital, all patients should not only have their history of medication explored but be asked specific questions around buying medicines from the Internet which could give rise to contra-indications that would otherwise be unknown

Status of the European and Finnish Medicines Verification Systems - variable progress made



Alert rate



Note: the objective for the EMVS countries is to reach an alert rate of less than 0.05%


30th September 2020

Patient safety and the implementation of the falsified medicines directive in the hospital




The key take-home messages can be summarised as follows: the number of "Alerts" (this is where, on decommissioning, the system does not authenticate the unique serialised data matrix on the prescription pack) still varied greatly between countries, with four countries having alert rates of greater than 1%. The positive news that the overall trend was downwards as more and more technical issues were resolved.

End-users not connected



Those manufacturers who had signed Participant Agreements and those who were connected to the hubs were steadily rising. The estimated number of product codes to cover all prescription packs across Europe was believed to have been achieved, notwithstanding the fact that this number will be in constant flux.




13

30th September 2020 Patient safety and the implementation of the falsified medicines directive in the hospital environment

Of further concern was that 22 countries were now beyond their "Stabilisation" periods and so theoretically open to national fines.





A positive picture in Finland revealed that the percentage of alerts starting from February 2019 was very low at 0.08%.

However, these alerts are not due to falsified medicines but because of scanning, data management and non-EU serialised packs' issues. Transactions, however, had stabilised at just below 15,000 per month. A final room-for-improvement slide focused on the area of aggregation, quality issues (e.g. packs with poor 2D quality backgrounds) combined with a precautionary warning around the need for forward planning pending the arrival of a COVID-19 vaccine.

The challenges and benefits of implementing the FMD



The report entitled "Benefits beyond the EU FMD - The Hospital Setting" revealed that the installation of robotics and conveyor systems which automate the verification and decommissioning of products brings a halo of benefits. Product identification, barcodes and interoperable data models were identified as being increasingly important as the use of technology advances.

The use of barcodes in healthcare has increased dramatically over the past 5-10 years and hospitals across Europe and worldwide are implementing programmes which deliver:

- ★ Improved patient safety
- ★ Enhanced clinical effectiveness
- ★ Operational efficiencies
- ★ Improved product recalls

The focus within hospitals is now starting to shift beyond simple compliance to the legislation and on to leveraging the EU FMD infrastructure to deliver additional benefits.


Standardisation is proving key to intra-operability across systems

The EU FMD has brought about the standardisation of medicinal product identification, common 2D barcodes which include the product code, batch/lot and expiry information on all prescription product packs and product master data availability. Without such rigorous standards, data and enforcement, hospitals were previously faced with disparate sorts of information in barcodes that effectively made them unusable in practical terms. The EU FMD enables hospitals to leverage further benefits opportunities which were difficult to realise without this level of harmonisation and barcoding prevalence, including:

- **★** Packs more easily transformed and repacked into kits and unit packs
- **★** Reduced errors during data capture and pack handling
- **★** 2D barcode provides opportunity to web enable digital content for multiple usage
- **★** Traceability using scanning can improve product recall
- ★ Closer integration with existing processes which require the capture of product code, batch/lot and expiry
- **★** More use of automation equipment and robotics
- **★** Access to digital data and services leveraging the barcode
- \star Increased interoperability through product identification and data

Benefit mapping to maximise FMD implementation potential

The benefits of implementing the FMD in hospitals can be summarised by a "benefit map" shown opposite. Detailed analysis of achieving these benefits is contained in the report and is recommended reading.



The level of medical errors which occur in hospitals is well documented, with experts estimating around 100,000 deaths a year. The financial costs are also significant for a hospital, resulting from factors including corrective treatment, litigation costs and additional hospital stays, the UK alone reports 2 billion euros per year are spent on avoidable hospital stays. There are also broader economic factors to consider such as loss of the ability of the patient to work and contribute to society. In developed countries, medication errors occur in around 10% to 20% of all patient administrations.

Medication errors can lead to an adverse drug event (ADE), of which there are estimated to be around 25 million worldwide. These ADE's can have serious impacts on patients, leading to physical and mental harm, long-term disabilities and even fatalities. The personal impacts are significant not only for the patient and their families but also for the healthcare workers involved; sadly this human aspect is often overlooked but a real factor in the impact errors have.

Grant Courtney, author of the report, emphasised the following: "The ability to identify and trace a medicine is therefore essential"

Cost savings

Other areas of operations are also shown to benefit with increased efficiencies and reduced waste. A major hospital that had implemented automated inventory management system reported a much greater level of control and visibility of the supply chain.

"So far, this hospital has saved €4.4 million on reduction of waste through over-ordering. Other hospitals are also delivering savings with one having saved €360K related to stock management and another with a €915K opportunity to increase chargeback revenue vs the previous year."

Practical hurdles and challenges of implementing the FMD in a French and UK hospital

Julia Asplin, Pharmacy Logistics Lead and Purchasing Team manager Lister Hospital Stevenage, UK





Business case / Funding / Resources

Before embarking on implementing the FMD, it is crucial to undertake a full appraisal of the options available. This entails research of technology packages, quantification of hardware and scanner options. This enables a full understanding of what is required and the costs associated which contribute to the overall plan and which can then be presented to the regional health authority in your country.

Operational overview

It is important as part of the planning process to assess the advantages of reconfiguring the workflow (capacity for the flow of packs and area required for an automated system. This will of course vary depending on product opted for). The capability of the different robotic systems will determine the different synergies that can be realised from automation.


Any new workflow with its governance rules requires a robust change management process. This requires strong leadership and a willingness to delegate and gain the maximum buy-in from staff with commensurate training. This is also a significant opportunity to introduce cultural change whereby a commitment of openness and honesty is established — in this way learnings can be seen as essential to instil an environment that respects continual improvement with subsequent efficiencies.

Having confidence in the ongoing IT support pre, per and post implementation is essential, therefore thorough testing of the system is required.

Anticipation of managing incidents following the 'go-live' needs careful planning. For instance, the correction processes for managing 'red' alerts or the interpretation of NMVS response codes requires robust SOPS.

All of the above needs to be planned out and captured on a single document. In the Lister Hospital case, an excel spreadsheet was used with the headings Task, Action, Deadline and comments (in which more granular plans can be placed).

FMD Project Plan



Key dates


Project start date June 2018
Project approved for implementation October 2019


Once the FMD project had been approved with the funding of 33,000 euros, secured procurement to complete the project could be made.


- ★ Software purchase initiated (go live was dependent on coordination with ongoing projects)
- ★ Equipment purchased and received December 2019
- ★ Phase 1 started August 2019 with Phase 10 completed August 2020


East & North Hertfordshire NHS Trust

Lister Hospital Goods In (Pharmacy Store)









Key elements / Checklist

1. Estates enabling works - Additional sockets for PCs + equipment (Ordered November 2019 - installed May 2020), FMD Workbench (Ordered November 2019 - installed May 2020)

2. IT support elements

- a. New Network Points required (Ordered October 2019 installed February 2020)
- b. Installation of new PCs required in two locations
- c. Installation of scanners Windows 10 not fully supported
- d. Roll out of EPMA affecting availability of IT resource to support FMD project
- e. Communication between software provider and local IT department

3. Process and workflow review

- a. Interpreting directive appropriate point to Verify + Decommission
- b. WDA Customer base impact/risk assessment
- c. Managing additional scan burden
- d. Staff Training

To underline the success of the implementation of the FMD, it is important to note that during this period various projects were running in parallel, namely a new pharmacy cold store installation and a pharmacy manufacturing unit refurbishment, which included an "Arrest" kit preparation area moved to the main store area whilst at the same time the aseptic compounding services were outsourced.

Due to the fact that there was no budget for the pharmacy re-configuration, the pharmacy team worked together to dismantle and reconstruct the storage system in the main store.

At the planning stage when the new workflows were being analysed, it became clear very quickly that the FMD work station required room for two PCs and a desk work area. The "Goods in" area was opened out so that the footprint was complete open plan.

Valerie Pelletier, hospital pharmacist, Supply Chain Manager, Rouen University Hospital





The ROUEN University Hospital is large and comprises 2,429 beds divided in to five locations. The central pharmacy manages the procurement and distribution of all the medicines, medical devices and PPE. Specifically with medicines, this means that on average 100,000 boxes at any one time are being stored.

The storage systems are split into two areas: one for manual storage on shelves and a second using an automated robotic dispensing system.



The staff manually scan each pack and the robot then automatically places it within the storage area having recorded the expiration date and the batch number. This scanning is the process whereby the pack is checked for its authenticity and is decommissioned. The anti-tampering device is checked visually at the time of scanning. It should be noted that some systems have an automatic feed and so the packs are simply loaded onto a conveyor belt and automatic scanning takes place relieving the manual burden. However manual scanning can be very quick and efficient, and this is achieved for the medicines stored on the shelves using a hand-held device. This requires additional staff time.

Combining the two storage references, a total of 1,538 packs are stored in the robot and 1,184 stored externally (but within a digital software system that is totally connected).

Currently, 81% of the prescription packs received from suppliers are FMD compliant (i.e. have a 2D barcode and a tamper-evident seal).

It is problematic that not all medicines have been uniquely serialised with a 2D barcode. In fact, a recent analysis revealed

that 22.2% of packs had no unique identifier. This is because some manufacturers have not yet serialised the packs. In some cases, this is due to long dated stock with very slow usage.

Challenges to be overcome

- 1. Packs wrapped in plastic film gives rise to time-wasting as it is not possible to scan through this material
- 2. In a carton following the scanning process, it sometimes fails to read all the boxes resulting in one pack not being decommissioned
- 3. For the manual decommissioning exercise, the practicalities are very difficult. One pallet of 286 cartons contains 675 boxes of medicine. The unpacking of each carton is time-consuming and a careful process needs to be adhered to if mistakes in double scanning or failure to scan happens
- 4. Computer network issues
- 5. Issues relating to reading/scanning the barcode
- 6. One incidence of a cyber attack occurred
- 7. Decommission failures (on average running at 3.6%)

Recommendations for the France hospital community

- 1. Medication errors can be significantly reduced following the automation of pack traceability. The investment is worth it on patient safety grounds with multiple benefits which includes fiscal savings. All France hospitals should be planning to provide a justification for investing in automation.
- 2. Improved quality of printing of 2D barcodes on packs to ensure consistent scanning capabilities
- 3. Aggregated codes on pallets would impact very positively on the decommissioning process
- 4. Manufacturers should now complete the serialisation of all prescription packs in line with the FMD (which is a mandatory requirement under national laws)
- 5. Further support needed to support error messages following scanning

Benefits found in hospitals following automation

- Automated solutions result in a reduced manual scanning burden of up to 63%
- No extra staff required to run a robotic system and frees time for resources to be directed towards improving pharmaceutical services
- Robotics allows:
 - Guaranteed inventory management
 - Reduced inventory resulting in cost savings
 - Improved ordering for bulk lines
 - A vital part of the medication process secured
 - Automatic decommissioning for a significant part of the internal supply chain
 - Visibility of recycled/returned products allows for analysis and subsequent improvements
- Utilisation of technology has across-the-board ramifications and opportunities for IT
- Redesigned workflows optimise "goods in" and "goods out"
- Very positive development of relationships with commercial provider to support development of NHS
- Adaptations ongoing to accommodate both FMD and local operational

EAASM Call to Action

We call upon all stakeholders to build on the implementation of the FMD by:

- ★ Encouraging all national and regional medical authorities to become even more involved to help ensure that any hospitals who need to support the implementation of the FMD do so;
- ★ Implementing a continuous improvement culture that involves inclusive collaboration with all staff and parties involved to capitalise on the many opportunities to use the data collected for positive patient care:
- ★ Procedural and system improvements by embracing technology such as Artificial Intelligence IT infrastructure to introduce automated dispensing solutions to save time and to alleviate the manual actions that lead to mental burden;
- ★ Introducing Smart applications to help connected services (ambulance, satellite hospitals) and robotics to aid the verification process and enhance the security of the medication use process;
- ★ Encouraging hospitals when onboarding patients to carry out a thorough discussion on the patients' medication history, to include questions around whether medicines have been bought on the Internet and thus introduce education to safeguard against patients taking themselves outside of their national health systems

If you would like to contact any of the speakers to enable you to help make choices about how to progress your implementation of the FMD please find their details below:



Andreas WALTER
General Manager of the European Medicines
Verification Organisation
andreas.walter@emvo-medicines.eu



Julia ASPLIN
Pharmacy Logistics Lead and Purchasing
Team Manager, The Lister Hospital,
Stevenage, UK
j.asplin@nhs.net



Maija GOHLKE-KOKKONEN
General Manager of the Finnish Medicines
Verification Organisation
maija.gohlke-kokkonen@laakevarmennus.fi



Valerie PELLETIER

Hospital Pharmacist, Supply Chain Manager,
Rouen University Hospital, France
valerie.pelletier@chu-rouen.fr



András SÜLE
Director of Finance at the European
Association of Hospital Pharmacists
andras.sule@eahp.eu



Agnès MATHIEU-MENDES
Deputy Head of the Unit on the quality, safety and innovation of medicinal products, DG SANTE, European Commission agnes.mathieu-mendes@ec.europa.eu



Grant COURTNEYPrinciple Consultant for Be4ward, expert supply chain transformation consultancy grant.courtney@be4ward.com

References

- 1. EUROPOL Newsroom €7.9 MILLION OF ILLEGAL PRODUCTS SEIZED IN A HIT AGAINST MEDICINE TRAFFICKERS (not in capital letter please), March 2020 https://www.europol.europa.eu/newsroom/news/€79-million-of-illegal-products-seized-in-hit-against-medicinetraffickers#:~:text=€7.9 million of illegal products seized in a hit against medicine
- 2. Happy Curious study 2014
- 3. The Internet is drowning in COVID-19-related malware and phishing scams." Ars Technica, 16 March 2020, at: https://arstechnica.com/information-technology/2020/03/the-internet-is-drowning-in-covid-19-related-malware-and-phishing-scams/and and the state of the state o"Coronavirus Used in Malicious Campaigns." Trend Micro, 20 March 2020, at:https://www.trendmicro.com/vinfo/us/security/news/cybercrimeand-digital-threats/coronavirus-used-in-spam-malware-file-names-and-malicious-domains
- 4. Trends in Trade in Counterfeit and Pirated Goods https://euipo.europa.eu/ohimportal/en/web/observatory/trends-in-trade-in-counterfeit-and-pirated-goods
- 5. https://nabp.pharmacy/wp-content/uploads/2020/05/Rogue-Rx-Activity-Report-May-2020.pdf
- 6. ASOP EU and EAASM data on file 2018
- .Pharmacy Verified Websites https://nabp.pharmacy/programs/dotpharmacy/
- 8. Grant Courtney Benefits beyond the EU Falsified Medicines Directive in the hospital setting Be4ward September 2020 Release 1.1 https://www.be4ward.com/expert-publishing/
- 9. Medicine Shortages: From Assumption to Evidence to Action A Proposal for Using the FMD Data Repositories for Shortages Monitoring François Bouvy and Mihai Rotaru* Frontiers In Medicine POLICY AND PRACTICE REVIEWS published: 03 February 2021 doi: 10.3389/ fmed.2021.579822

Acknowledgements

This report has been made possible by an unrestricted educational grant from Becton Dickinson SA.

www.eaasm.eu

Copyright © December 2020 European Alliance for Access to Safe Medicines

All rights reserved. No part of this publication may be translated, reproduced or transmitted in any form or by any other means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without the consent of the EAASM.

All correspondence regarding this publication should be sent to:

EAASM 1386 London Road Leigh-on-Sea Essex SS9 2UJ IJK

Contact Directly: Mike Isles mike.isles@eaasm.eu +44 (0) 7540 462867

> Laura Cigolot laura.cigolot@eaasm.eu

